Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
UCB augments its scientific standing in the targeting of protein-protein interactions with small molecules through back-to-back new publications in Nature Communications. You can read the publications here (https://t.co/FhPYdqEjal) and here (https://t.co/
— UCB News (@ucb_news) 03.03.2021 -
Our new collaboration with Microsoft will equip us to meet the world’s biggest healthcare challenges. I can truly dare to hope we are standing at the edge of a new dawn in how we develop life-changing therapies https://t.co/5oV3V0Hvpa https://t.co/c8WLpP1
— UCB News (@ucb_news) 02.03.2021 -
UCB is committed to better understanding the unique experiences and needs of people living with rare diseases. Thank you for sharing your stripes on #RareDiseaseDay. Through your support and our collaborative efforts we will continue to shine a light on r
— UCB News (@ucb_news) 01.03.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
